DexCom, Inc. Dossier
Qualitative Analysis
Business overview
DexCom, Inc. is a pioneer and global leader in continuous glucose monitoring (CGM) systems. Founded in 1999 and headquartered in San Diego, California, the company designs, develops, and commercializes biosensing technologies that transform diabetes management and metabolic health tracking. Its core product portfolio includes the Dexcom G7 and G7 15 Day CGM systems, which provide real-time glucose readings, trends, and predictive alerts to help users manage their health with confidence. Additionally, Dexcom has expanded into the over-the-counter consumer wellness space with its Stelo platform, targeting non-insulin-using type 2 diabetics and health-conscious individuals. The company operates internationally, leveraging manufacturing facilities in the United States, Malaysia, and Ireland to support its growing global customer base.
Research as of 5 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Extend the nonprescription glucose-biosensing platform into the United Kingdom, Australia, New Zealand, and South Korea, complementing the reimagined Stelo application introduced in the United States.
Expected impact: Broaden Dexcom's addressable market beyond insulin-treated diabetes and establish additional direct-to-consumer metabolic-health channels.
Develop and evaluate a digital-health program integrating Dexcom G7 and Stelo glucose data with contextual information covering nutrition, physical activity, sleep, and stress.
Expected impact: Generate real-world evidence for personalized care, earlier intervention, and screening applications involving prediabetes and Type 2 diabetes.
Add registered-dietitian access, personalized nutrition guidance, and behavior-change support to Dexcom's glucose-biosensing ecosystem through the planned acquisition of Nutrisense.
Expected impact: Connect food choices with glucose responses and extend Dexcom's offering from sensor data toward personalized metabolic-health support.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Dexcom stated that acquiring Nutrisense would add registered dietitians, personalized nutrition guidance, and behavior-change support, strengthening its ability to link food choices with glucose responses.
Strategic Partnerships
The partnership is designed to combine Dexcom glucose data with Oura Ring information on sleep, stress, heart health, activity, and other biometrics to provide shared users with a broader view of metabolic health.
Terms: Dexcom committed a $75 million investment in ŌURA's Series D financing; the companies disclosed that the financing valued ŌURA at more than $5 billion.